Theralase Technologies Expands Bladder Cancer Study in Canada

Theralase Technologies Inc. has inaugurated a new clinical study site at St. Joseph's Healthcare Hamilton, Canada, focusing on its Anti-Cancer Therapy for bladder cancer treatment. The company's lead drug, RuvidarTM, activated by the TLC-3200 Medical Laser System, is under investigation in Phase II trials targeting BCG-resistant non-muscle invasive bladder cancer (NMIBC).

Theralase has enrolled and treated 75 patients, with 61.9% achieving complete response at some point during the trial. Moreover, 43.6% of patients maintained their complete response for at least 12 months. Importantly, no serious adverse events associated with the treatment were reported.

The company's research is progressing in both Canada and the US, with additional sites planned. The goal is to commercialize Ruvidar on a global scale, providing an alternative to radical surgery.